Care management for complex needs may not cut readmissions

Care management for complex needs may not cut readmissions

January 15, 2020 Care management for complex needs may not cut readmissions (HealthDay)—Among patients with very high use of health care services, readmission rates were not lower for those assigned to a care-transition program compared with usual care, according to a study published in the Jan. 9 issue of the New England Journal of Medicine . Amy Finkelstein, Ph.D., from the Massachusetts Institute of Technology in Cambridge, and colleagues randomly assigned 800 hospitalized patients with medically and socially complex conditions and at least one additional hospitalization in the preceding six months to a care-transition program or to usual care. The evaluation measured the impact of the Camden Coalition's care management program (Camden Core Model) on the 180-day hospital readmission rate. The researchers found that the 180-day readmission rate was 62.3 percent in the intervention group and 61.7 percent in the control group ; the adjusted between-group difference was not significant (0.82 percentage points; 95 percent confidence interval, −5.97 to 7.61). A comparison of the intervention-group admissions during the six months before and after enrollment misleadingly suggested a 38-percentage-point decline in admissions; but this comparison did not account for the similar decline in the control group. "This study confirms what our care teams see every day—care management that focuses solely on health care is insufficient," Kathleen Noonan, chief executive officer of the Camden Coalition, said in a statement. "People with lifetimes of trauma and complexity are best supported by high-quality resources in the community and a health care environment designed to meet their needs." Explore further



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More